This technology constructs a patient-derived tumor organoid chip (Patient-derived Tumoroids on a Chip, PTOC) for personalized rapid chemotherapeutic drug screening. The first part in this project is to build anti-CEA which is able to predict tumor metastasis factorsdrug treatment effects. The second part is to develop personalized antigen-capturing particles (ACPs) based on PTOC as a powerful adjuvant for immunotherapy. On PTOC, APCs are used to promote efficient delivery to dendritic cellsantigen-presenting cells to enhance the overall immune responseovercome the low tumor immune response. The immunomodulators integrated to the medical equipment provide the opportunity to open a new avenue for precise tumor immunotherapy.

This technology constructs a patient-derived tumor organoid chip (Patient-derived Tumoroids on a Chip, PTOC) for personalized rapid chemotherapeutic drug screening. The first part in this project is to build anti-CEA which is able to serve as nano sensors to evaluate the performance of various antibodies, cytokineexosomes, facilitating to predict tumor metastasis factorsdrug treatment effects. The second part is to develop personalized antigen-capturing particles (ACPs) based on PTOC as a powerful adjuvant for immunotherapy.

This technology is cut at the level of another simulated metastasis chip, a simulated tumor microenvironment chip (Patient-derived Tumoroids Microenvironment on a Chip, PT-MOC), which is used for personalized rapid chemotherapy drug screening, tumor metastasis factor assessment, as a prediction of tumor in drug treatment. The subsequent evaluation of the responsemetastasis probability is very helpful for precision medicinenew drug development, especially in metastatic tumorsimmunotherapy.